New! Sign up for our free email newsletter.
Science News
from research organizations

Psychedelic experience may not be required for psilocybin's antidepressant-like benefits

So-called 'magic mushroom' drug seems to work through multiple brain mechanisms for its different effects

Date:
April 13, 2021
Source:
University of Maryland School of Medicine
Summary:
Researchers have shown that psilocybin -- the active chemical in 'magic mushrooms' -- still works its antidepressant-like actions, at least in mice, even when the psychedelic experience is blocked. The new findings suggest that psychedelic drugs work in multiple ways in the brain and it may be possible to deliver the fast-acting antidepressant therapeutic benefit without requiring daylong guided therapy sessions.
Share:
FULL STORY

University of Maryland School of Medicine (UMSOM) researchers have shown that psilocybin -- the active chemical in "magic mushrooms" -- still works its antidepressant-like actions, at least in mice, even when the psychedelic experience is blocked. The new findings suggest that psychedelic drugs work in multiple ways in the brain and it may be possible to deliver the fast-acting antidepressant therapeutic benefit without requiring daylong guided therapy sessions. A version of the drug without, or with less of, the psychedelic effects could loosen restrictions on who could receive the therapy, and lower costs, making the benefits of psilocybin more available to more people in need.

In all clinical trials performed to date, the person treated with psilocybin remains under the care of a guide, who keeps the person calm and reassures them during their daylong experience. This can include hallucinations, altered perception of time and space, and intense emotional and spiritual encounters.

Researchers in the field have long attributed psilocybin's effectiveness to the intense psychedelic experience.

"We do not understand the mechanisms that underlie the antidepressant actions of psilocybin and the role that the profound psychedelic experience during these sessions plays in the therapeutic benefits," says Scott Thompson, Ph.D., Professor and Chair, Department of Physiology at UMSOM and senior author of the study. "The psychedelic experience is incredibly powerful and can be life-changing, but that could be too much for some people or not appropriate."

Several barriers prevent the wide-spread use of psychedelic compounds. For example, there is fear that the psychedelic experience may promote psychosis in people who are predisposed to severe mental disorders, like bipolar disorder and schizophrenia, so the clinical therapy sessions performed to-date have been limited to a highly selected screened group without a family history of these disorders.

Dr. Thompson adds that there may also be an equity issue because not everyone can take several days off work to prepare and engage in the experience. The costs of staffing a facility with at least one trained guide per treated person per day and a private space may also be prohibitive to all but a few. He says it is conceivable that a depression treatment derived from psilocybin could be developed without the psychedelic effects so people can take it safely at home without requiring a full day in a care facility.

For their study, led by UMSOM MD/PhD student Natalie Hesselgrave, the team used a mouse model of depression in which mice were stressed for several hours a day over 2-3 weeks. Because researchers cannot measure mouse moods, they measure their ability to work for rewards, such as choosing to drink sugar water over plain water. People suffering from depression lose the feeling of pleasure for rewarding events. Similarly, stressed mice no longer preferred sugar water over plain water. However, 24 hours after a dose of psilocybin, the stressed mice regained their preference for the sugar water, demonstrating that the drug restored the mice's pleasure response.

Psilocybin exerts its effects in people by binding to and turning on receptors for the chemical messenger serotonin. One of these receptors, the serotonin 2A receptor, is known to be responsible for the psychedelic response. To see if the psychedelic effects of psilocybin were needed for the anti-depressive benefits, the researchers treated the stressed mice with psilocybin together with a drug, ketanserin, which binds to the serotonin 2A receptor and keeps it from being turned on. The researchers found that the stressed mice regained their preference for the sugar water in response to psilocybin, even without the activation of the psychedelic receptor.

"These findings show that activation of the receptor causing the psychedelic effect isn't absolutely required for the antidepressant benefits, at least in mice," says Dr. Thompson, "but the same experiment needs to be performed in depressed human subjects." He says his team plans to investigate which of the 13 other serotonin receptors are the ones responsible for the antidepressant actions.

"This new study has interesting implications, and shows that more basic research is needed in animals to reveal the mechanisms for how these drugs work, so that treatments for these devastating disorders can be developed" says Albert E. Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, University of Maryland Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine.

This work was funded by the National Institute of Mental Health (R01 MH086828) and the National Institute of General Medical Sciences (T32 GM092237).

Although not approved yet, Dr. Thompson and the University of Maryland Baltimore have filed a patent on using psilocybin with drugs that block serotonin 2A receptors to treat depression.


Story Source:

Materials provided by University of Maryland School of Medicine. Original written by Vanessa McMains. Note: Content may be edited for style and length.


Journal Reference:

  1. Natalie Hesselgrave, Timothy A. Troppoli, Andreas B. Wulff, Anthony B. Cole, Scott M. Thompson. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proceedings of the National Academy of Sciences, 2021; 118 (17): e2022489118 DOI: 10.1073/pnas.2022489118

Cite This Page:

University of Maryland School of Medicine. "Psychedelic experience may not be required for psilocybin's antidepressant-like benefits." ScienceDaily. ScienceDaily, 13 April 2021. <www.sciencedaily.com/releases/2021/04/210413114107.htm>.
University of Maryland School of Medicine. (2021, April 13). Psychedelic experience may not be required for psilocybin's antidepressant-like benefits. ScienceDaily. Retrieved March 28, 2024 from www.sciencedaily.com/releases/2021/04/210413114107.htm
University of Maryland School of Medicine. "Psychedelic experience may not be required for psilocybin's antidepressant-like benefits." ScienceDaily. www.sciencedaily.com/releases/2021/04/210413114107.htm (accessed March 28, 2024).

Explore More

from ScienceDaily

RELATED STORIES